Baxter International Inc.

NYSE:BAX  
73.23
+0.63 (+0.87%)
Products

Baxter Says Submitted Responses To Additional Information Requests From FDA Related To New Novum IQ Infusion Platform

Published: 03/22/2022 21:32 GMT
Baxter International Inc. (BAX) - Baxter - Submitted Responses to Additional Information Requests From FDA With Respect to Two 510(k) Applications for New Novum Iq Infusion Platform.
Baxter International Inc - Expects FDA to Respond on Two Submissions by End of April 2022.
Baxter International Inc - Intends to Launch Novum Lvp in United States Shortly After Receiving Clearance From FDA.
Baxter International Inc - Preparing to Submit Responses to Additional Information Requests From FDA With Respect to Novum Iq Syringe Pump in Q2.
Further Company Coverage: Baxn ((reuters.
Briefs@thomsonreuters.
Com;)).